Latvia Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Latvia Pharmaceuticals and Healthcare Report Q3 2013 Jun 19th 2013, 00:00 BMI View: While we remain of the opinion that Latvia’s economy will continue to recover in 2013 and beyond, we are relatively cautious regarding the performance of its pharmaceutical market. For example, elevated unemployment will have a negative effect both on private and public (through lower tax revenues) spending on healthcare in general, particularly impacting services and treatments not covered by reimbursement. We note that private spending – of which the majority comprises out-of-pocket payments – accounts for over 40% of the total healthcare expenditure in the country. Headline Expenditure Projections ?? Pharmaceuticals: LVL218mn (US$391mn) in 2012 to LVL226mn (US$400mn) … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=103195. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/latvia-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions